News

Update: July 7, 2022: Following Health Canada’s approval of ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c), CADTH posted reimbursement recommendations for ALBRIOZA (AMX0035) in late June. ALS Canada provided feedback on the recommendations, bringing forward the perspectives…

Make your voice heard! The Canadian Agency for Drugs and Technology in Health (CADTH) has posted a call for patient input on AMX0035. ALS Canada will be preparing a submission reflecting the perspectives of the ALS community and we are…

November 1, 2021 – The Phase 3 VALOR results for tofersen did not show a statistically significant change in disease progression as assessed by the ALSFRS-R scale, however a number of other outcome measures suggested the treatment was able to…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the October 2021 Research Update, you’ll learn about the progress researchers have made in…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

The 2021 federal election is wrapping up in less than a week! With Election Day scheduled for Monday, September 20, 2021, now more than ever, it’s important to know the issues that matter to you before you cast your vote. ALS…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…